America and Britain Reach Tariff-Free Arrangement on Pharmaceuticals.
The UK and US have agreed to a landmark trade agreement that will guarantee zero levies on UK medicine products going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to raise expenditure on drugs through the NHS. This pledge secures that tariffs on these vital goods will stay at zero for a period of three years.
This deal is in response to recent warnings to hike import taxes on branded drug imports, with figures mentioned as high as double the cost.
"This agreement between the UK reinforces the worldwide climate for new treatments and establishes much-needed equity to transatlantic medicine commerce," a release said.
Commercial Impact
Drugs constitute one of the the United Kingdom's largest goods shipped to the United States, which is clearly the largest buyer for major companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period to the end of September, the UK sold medicines valued at billions to the US. This amount accounted for a significant portion of British export trade in that span.
"This agreement safeguards employment, boosts funding and sets the stage for the UK to emerge as a international leader for life sciences," a government official remarked.
Specific British Pledges
The deal involves several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to increase overall public funding on drugs from 0.3% of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The amount manufacturers must refund to the NHS to control costs will be capped at 15%. In the past, rebates were more than 20%.
Recent Tensions
This agreement comes amid a long-running tension between the drug companies and the UK government over spending levels and regulatory access.
The disagreement were exacerbated by claims that American customers were paying a premium for the identical medicines than people in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been delayed or cancelled, while substantial funding commitments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a proportion of its overall budget over the past decade.
